PI3K亚型在CD8+ T细胞发育和功能中的作用

Pankaj Gaur, Mikayel Mkrtichyan, Vivek Verma, Nazli Jafarzadeh, Mariana Hattar, Seema Gupta, Samir N Khleif
{"title":"PI3K亚型在CD8+ T细胞发育和功能中的作用","authors":"Pankaj Gaur,&nbsp;Mikayel Mkrtichyan,&nbsp;Vivek Verma,&nbsp;Nazli Jafarzadeh,&nbsp;Mariana Hattar,&nbsp;Seema Gupta,&nbsp;Samir N Khleif","doi":"10.1007/978-3-031-06566-8_9","DOIUrl":null,"url":null,"abstract":"<p><p>CD8<sup>+</sup> T cells are an essential part of the immune system and play a vital role in defending against tumors and infections. The phosphoinositide-3-kinase (PI3K), especially class I, is involved in numerous interrelated signaling pathways which control CD8<sup>+</sup> T cell development, maturation, migration, activation, and differentiation. While CD8<sup>+</sup> T lymphocytes express all class I PI3K isoforms (PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ), isoform-specific functions, especially for PI3Kα and PI3Kβ have not been fully elucidated. A few studies suggest the important role of p110δ and p110γ in CD8<sup>+</sup> T cell activation, signaling, chemotaxis and function and several clinical trials are currently testing the effect of isoform-specific inhibitors in various types of cancers, including Indolent Non-Hodgkin Lymphoma, Peripheral T cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, non-small cell lung carcinoma (NSCLC), head & neck cancer, and breast cancer. This chapter summarizes current knowledge of the roles of various PI3K isoforms and downstream signaling pathways in regulating CD8<sup>+</sup> T cell fate, including cell proliferation, migration, and memory generation. We also discuss certain clinical trials employing PI3K inhibitors for cancer therapy, their limitations, and future perspectives.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"PI3K Isoforms in CD8<sup>+</sup> T Cell Development and Function.\",\"authors\":\"Pankaj Gaur,&nbsp;Mikayel Mkrtichyan,&nbsp;Vivek Verma,&nbsp;Nazli Jafarzadeh,&nbsp;Mariana Hattar,&nbsp;Seema Gupta,&nbsp;Samir N Khleif\",\"doi\":\"10.1007/978-3-031-06566-8_9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>CD8<sup>+</sup> T cells are an essential part of the immune system and play a vital role in defending against tumors and infections. The phosphoinositide-3-kinase (PI3K), especially class I, is involved in numerous interrelated signaling pathways which control CD8<sup>+</sup> T cell development, maturation, migration, activation, and differentiation. While CD8<sup>+</sup> T lymphocytes express all class I PI3K isoforms (PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ), isoform-specific functions, especially for PI3Kα and PI3Kβ have not been fully elucidated. A few studies suggest the important role of p110δ and p110γ in CD8<sup>+</sup> T cell activation, signaling, chemotaxis and function and several clinical trials are currently testing the effect of isoform-specific inhibitors in various types of cancers, including Indolent Non-Hodgkin Lymphoma, Peripheral T cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, non-small cell lung carcinoma (NSCLC), head & neck cancer, and breast cancer. This chapter summarizes current knowledge of the roles of various PI3K isoforms and downstream signaling pathways in regulating CD8<sup>+</sup> T cell fate, including cell proliferation, migration, and memory generation. We also discuss certain clinical trials employing PI3K inhibitors for cancer therapy, their limitations, and future perspectives.</p>\",\"PeriodicalId\":11102,\"journal\":{\"name\":\"Current topics in microbiology and immunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current topics in microbiology and immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/978-3-031-06566-8_9\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in microbiology and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/978-3-031-06566-8_9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 1

摘要

CD8+ T细胞是免疫系统的重要组成部分,在抵抗肿瘤和感染方面发挥着至关重要的作用。磷酸肌醇-3-激酶(PI3K),尤其是I类,参与了许多相互关联的信号通路,这些信号通路控制CD8+ T细胞的发育、成熟、迁移、激活和分化。虽然CD8+ T淋巴细胞表达所有I类PI3K亚型(PI3Kα、PI3Kβ、PI3Kδ和PI3Kγ),但亚型特异性功能,特别是PI3Kα和PI3Kβ的特异性功能尚未完全阐明。一些研究表明p110δ和p110γ在CD8+ T细胞活化、信号转导、趋化和功能中的重要作用,目前一些临床试验正在测试异型特异性抑制剂在各种类型癌症中的作用,包括惰性非霍奇金淋巴瘤、外周T细胞淋巴瘤、慢性淋巴细胞白血病、小淋巴细胞淋巴瘤、非小细胞肺癌(NSCLC)、头颈癌和乳腺癌。本章总结了目前关于各种PI3K亚型和下游信号通路在调节CD8+ T细胞命运中的作用的知识,包括细胞增殖、迁移和记忆产生。我们还讨论了使用PI3K抑制剂治疗癌症的某些临床试验,它们的局限性和未来的前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PI3K Isoforms in CD8+ T Cell Development and Function.

CD8+ T cells are an essential part of the immune system and play a vital role in defending against tumors and infections. The phosphoinositide-3-kinase (PI3K), especially class I, is involved in numerous interrelated signaling pathways which control CD8+ T cell development, maturation, migration, activation, and differentiation. While CD8+ T lymphocytes express all class I PI3K isoforms (PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ), isoform-specific functions, especially for PI3Kα and PI3Kβ have not been fully elucidated. A few studies suggest the important role of p110δ and p110γ in CD8+ T cell activation, signaling, chemotaxis and function and several clinical trials are currently testing the effect of isoform-specific inhibitors in various types of cancers, including Indolent Non-Hodgkin Lymphoma, Peripheral T cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, non-small cell lung carcinoma (NSCLC), head & neck cancer, and breast cancer. This chapter summarizes current knowledge of the roles of various PI3K isoforms and downstream signaling pathways in regulating CD8+ T cell fate, including cell proliferation, migration, and memory generation. We also discuss certain clinical trials employing PI3K inhibitors for cancer therapy, their limitations, and future perspectives.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.60
自引率
0.00%
发文量
26
审稿时长
>12 weeks
期刊介绍: The review series Current Topics in Microbiology and Immunology provides a synthesis of the latest research findings in the areas of molecular immunology, bacteriology and virology. Each timely volume contains a wealth of information on the featured subject. This review series is designed to provide access to up-to-date, often previously unpublished information.
期刊最新文献
A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19. Alterations of the AKT Pathway in Sporadic Human Tumors, Inherited Susceptibility to Cancer, and Overgrowth Syndromes. Evidence for the Efficacy of COVID-19 Convalescent Plasma. HemoClear: A Practical and Cost-Effective Alternative to Conventional Convalescent Plasma Retrieval Methods. Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1